JP Morgan Chase’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $402K | Buy |
37,680
+19,042
| +102% | +$294K | ﹤0.01% | 5152 |
|
|
2025
Q4 | $379K | Sell |
18,638
-153,303
| -89% | -$2.69M | ﹤0.01% | 5198 |
|
|
2025
Q3 | $2.72M | Buy |
171,941
+124,287
| +261% | +$1.84M | ﹤0.01% | 3847 |
|
|
2025
Q2 | $636K | Sell |
47,654
-2,552,803
| -98% | -$34.5M | ﹤0.01% | 4646 |
|
|
2025
Q1 | $26.5M | Buy |
2,600,457
+2,387,026
| +1,118% | +$27.7M | ﹤0.01% | 1700 |
|
|
2024
Q4 | $3.38M | Buy |
213,431
+182,314
| +586% | +$9.47M | ﹤0.01% | 3734 |
|
|
2024
Q3 | $1.81M | Buy |
31,117
+422
| +1% | +$20.8K | ﹤0.01% | 4078 |
|
|
2024
Q2 | $1.4M | Sell |
30,695
-24,715
| -45% | -$1.33M | ﹤0.01% | 4045 |
|
|
2024
Q1 | $3.67M | Sell |
55,410
-7,234
| -12% | -$429K | ﹤0.01% | 3357 |
|
|
2023
Q4 | $2.49M | Buy |
62,644
+9,575
| +18% | +$300K | ﹤0.01% | 3667 |
|
|
2023
Q3 | $1.69M | Buy |
53,069
+23,379
| +79% | +$873K | ﹤0.01% | 3672 |
|
|
2023
Q2 | $1.19M | Buy |
29,690
+6,270
| +27% | +$275K | ﹤0.01% | 3915 |
|
|
2023
Q1 | $1M | Sell |
23,420
-18,061
| -44% | -$912K | ﹤0.01% | 4049 |
|
|
2022
Q4 | $1.99M | Buy |
41,481
+23,710
| +133% | +$1.11M | ﹤0.01% | 3558 |
|
|
2022
Q3 | $669K | Buy |
17,771
+2,547
| +17% | +$88.3K | ﹤0.01% | 4272 |
|
|
2022
Q2 | $420K | Sell |
15,224
-22,304
| -59% | -$979K | ﹤0.01% | 4672 |
|
|
2022
Q1 | $2.04M | Buy |
37,528
+4,329
| +13% | +$222K | ﹤0.01% | 3736 |
|
|
2021
Q4 | $1.94M | Buy |
33,199
+22,697
| +216% | +$1.13M | ﹤0.01% | 3887 |
|
|
2021
Q3 | $415K | Buy |
10,502
+1,231
| +13% | +$43.8K | ﹤0.01% | 4836 |
|
|
2021
Q2 | $393K | Buy |
9,271
+2,882
| +45% | +$156K | ﹤0.01% | 4844 |
|
|
2021
Q1 | $393K | Buy |
6,389
+555
| +10% | +$35.2K | ﹤0.01% | 4827 |
|
|
2020
Q4 | $411K | Buy |
5,834
+3,237
| +125% | +$204K | ﹤0.01% | 4483 |
|
|
2020
Q3 | $102K | Buy |
2,597
+254
| +11% | +$10.1K | ﹤0.01% | 4682 |
|
|
2020
Q2 | $88K | Buy |
+2,343
| New | +$72.2K | ﹤0.01% | 4621 |
|
Other funds holding KROS
NCM
VCM
O
VPM
MAP